ALK-Abelló A/S (AKBLF)
USD 22.05
(0.0%)
USD 22.05
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 291 Million DKK | -38.74% |
| 2022 | 475 Million DKK | -7.95% |
| 2021 | 516 Million DKK | -20.0% |
| 2020 | 645 Million DKK | -4.3% |
| 2019 | 674 Million DKK | 51.12% |
| 2018 | 446 Million DKK | -25.17% |
| 2017 | 596 Million DKK | 23.4% |
| 2016 | 483 Million DKK | 2.99% |
| 2015 | 469 Million DKK | 1240.0% |
| 2014 | 35 Million DKK | 133.33% |
| 2013 | 15 Million DKK | 110.34% |
| 2012 | -145 Million DKK | 65.48% |
| 2011 | -420 Million DKK | -107.92% |
| 2010 | -202 Million DKK | 47.4% |
| 2009 | -384 Million DKK | 10.49% |
| 2008 | -429 Million DKK | 55.36% |
| 2007 | -961 Million DKK | 2.44% |
| 2006 | -985 Million DKK | 81.94% |
| 2005 | -5.45 Billion DKK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 227 Million DKK | -21.99% |
| 2024 Q2 | 87 Million DKK | -61.67% |
| 2023 Q3 | 511 Million DKK | -9.56% |
| 2023 Q1 | 448 Million DKK | -5.68% |
| 2023 FY | 291 Million DKK | -38.74% |
| 2023 Q4 | 291 Million DKK | -43.05% |
| 2023 Q2 | 565 Million DKK | 26.12% |
| 2022 Q3 | 429 Million DKK | -3.38% |
| 2022 Q2 | 444 Million DKK | -8.83% |
| 2022 Q1 | 487 Million DKK | -5.62% |
| 2022 FY | 475 Million DKK | -7.95% |
| 2022 Q4 | 475 Million DKK | 10.72% |
| 2021 Q3 | 566 Million DKK | -2.25% |
| 2021 Q4 | 516 Million DKK | -8.83% |
| 2021 FY | 516 Million DKK | -20.0% |
| 2021 Q1 | 560 Million DKK | -13.18% |
| 2021 Q2 | 579 Million DKK | 3.39% |
| 2020 FY | 645 Million DKK | -4.3% |
| 2020 Q1 | 663 Million DKK | -1.63% |
| 2020 Q2 | 679 Million DKK | 2.41% |
| 2020 Q3 | 778 Million DKK | 14.58% |
| 2020 Q4 | 645 Million DKK | -17.1% |
| 2019 Q3 | 833 Million DKK | -1.3% |
| 2019 Q2 | 844 Million DKK | 25.78% |
| 2019 Q4 | 674 Million DKK | -19.09% |
| 2019 Q1 | 671 Million DKK | 50.45% |
| 2019 FY | 674 Million DKK | 51.12% |
| 2018 Q2 | 615 Million DKK | 5.49% |
| 2018 FY | 446 Million DKK | -25.17% |
| 2018 Q3 | 557 Million DKK | -9.43% |
| 2018 Q4 | 446 Million DKK | -19.93% |
| 2018 Q1 | 583 Million DKK | -2.18% |
| 2017 FY | 596 Million DKK | 23.4% |
| 2017 Q3 | 674 Million DKK | 28.63% |
| 2017 Q1 | 644 Million DKK | 33.33% |
| 2017 Q4 | 596 Million DKK | -11.57% |
| 2017 Q2 | 524 Million DKK | -18.63% |
| 2016 Q2 | 406 Million DKK | 11.23% |
| 2016 FY | 483 Million DKK | 2.99% |
| 2016 Q3 | 481 Million DKK | 18.47% |
| 2016 Q4 | 483 Million DKK | 0.42% |
| 2016 Q1 | 365 Million DKK | -22.17% |
| 2015 Q4 | 469 Million DKK | 89.11% |
| 2015 Q1 | 83 Million DKK | 137.14% |
| 2015 Q2 | 197 Million DKK | 137.35% |
| 2015 Q3 | 248 Million DKK | 25.89% |
| 2015 FY | 469 Million DKK | 1240.0% |
| 2014 Q1 | 36 Million DKK | 140.0% |
| 2014 Q2 | 27 Million DKK | -25.0% |
| 2014 Q3 | 86 Million DKK | 218.52% |
| 2014 Q4 | 35 Million DKK | -59.3% |
| 2014 FY | 35 Million DKK | 133.33% |
| 2013 Q2 | 37 Million DKK | 132.17% |
| 2013 FY | 15 Million DKK | 110.34% |
| 2013 Q4 | 15 Million DKK | -78.57% |
| 2013 Q3 | 70 Million DKK | 89.19% |
| 2013 Q1 | -115 Million DKK | 20.69% |
| 2012 Q4 | -145 Million DKK | 11.59% |
| 2012 FY | -145 Million DKK | 65.48% |
| 2012 Q1 | -379 Million DKK | 9.76% |
| 2012 Q2 | -159 Million DKK | 58.05% |
| 2012 Q3 | -164 Million DKK | -3.14% |
| 2011 Q4 | -420 Million DKK | -14.75% |
| 2011 Q1 | -471 Million DKK | -133.17% |
| 2011 Q2 | -394 Million DKK | 16.35% |
| 2011 Q3 | -366 Million DKK | 7.11% |
| 2011 FY | -420 Million DKK | -107.92% |
| 2010 Q1 | -373 Million DKK | 2.86% |
| 2010 FY | -202 Million DKK | 47.4% |
| 2010 Q4 | -202 Million DKK | -129.55% |
| 2010 Q3 | -88 Million DKK | 67.16% |
| 2010 Q2 | -268 Million DKK | 28.15% |
| 2009 Q4 | -384 Million DKK | 0.0% |
| 2009 FY | -384 Million DKK | 10.49% |
| 2008 FY | -429 Million DKK | 55.36% |
| 2007 FY | -961 Million DKK | 2.44% |
| 2006 FY | -985 Million DKK | 81.94% |
| 2005 FY | -5.45 Billion DKK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -1746.095% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -6966.496% |
| SQZ Biotechnologies Company | -36.23 Million USD | 903.024% |
| Evofem Biosciences, Inc. | 42.79 Million USD | -580.018% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 4715.733% |
| Mesoblast Limited | 55.85 Million USD | -420.961% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -31285.288% |
| Genus plc | 190.6 Million USD | -52.676% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -12915.289% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -23872.558% |
| Marizyme, Inc. | 18.56 Million USD | -1467.126% |
| ContraFect Corporation | -6.02 Million USD | 4929.074% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -42694.118% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -216033.513% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -25085.451% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -12878.134% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -5189.086% |
| MultiCell Technologies, Inc. | 90.04 USD | -323189593.47% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 39746.965% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -2147.799% |
| EV Biologics, Inc. | 1.36 Million USD | -21172.381% |
| Q BioMed Inc. | 4.06 Million USD | -7067.474% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | -852.412% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -46657.203% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -28777.184% |
| Biomind Labs Inc. | 711.4 Thousand USD | -40805.142% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 109.8 Million USD | -165.018% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -2172.268% |
| Skye Bioscience, Inc. | -5.72 Million USD | 5186.177% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -33727.73% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -208048.551% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -5051.929% |
| IMV Inc. | 7.67 Million USD | -3693.745% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -1464640.524% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -13115.373% |
| GB Sciences, Inc. | 1.74 Million USD | -16554.114% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 158434.603% |
| HST Global, Inc. | 96.79 Thousand USD | -300541.575% |
| CSL Limited | 10.52 Billion USD | 97.235% |
| Halberd Corporation | 144.72 Thousand USD | -200976.554% |
| Enzolytics Inc. | 981.65 Thousand USD | -29543.786% |
| Resverlogix Corp. | 6.45 Million USD | -4410.929% |
| Affymax, Inc. | -5.59 Million USD | 5299.214% |
| SYBLEU INC | 473.71 Thousand USD | -61329.47% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 43333.51% |
| argenx SE | -2.02 Billion USD | 114.343% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | -569.982% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 718.991% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -10643.498% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 3391.888% |
| AVAX Technologies, Inc. | -5.9 Million USD | 5029.524% |
| Zenith Capital Corp. | 10.06 Thousand USD | -2891394.436% |
| Genscript Biotech Corporation | -1.06 Billion USD | 127.418% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -145086.397% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -12095.97% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -176790.018% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | -380.628% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -14454.425% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 11422.816% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -80798.502% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | -1335.194% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 1588701.376% |
| BioStem Technologies, Inc. | 4.47 Million USD | -6407.14% |
| ONE Bio Corp. | 9.04 Million USD | -3119.014% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -144493.399% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 22213840.458% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -141013.487% |
| Agentix Corp. | 37.63 Thousand USD | -773198.61% |
| LadRx Corporation | -2.03 Million USD | 14389.439% |
| Cell Source, Inc. | 9.23 Million USD | -3052.09% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 1426011.407% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -45714.723% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -45714.723% |
| NovAccess Global Inc. | 2.17 Million USD | -13258.03% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -4015.417% |
| Itoco Inc. | 228.3 Thousand USD | -127361.072% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -213887.896% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -5770.486% |
| Kadimastem Ltd | -253.1 Thousand USD | 115073.41% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -72315.26% |
| CytoDyn Inc. | 20.26 Million USD | -1336.186% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 44976916.074% |
| Mobile Lads Corp. | 484.23 Thousand USD | -59995.161% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 3139820.813% |
| Qrons Inc. | 351.42 Thousand USD | -82705.248% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -3676.277% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 116677.197% |
| Rebus Holdings, Inc. | 305 Thousand USD | -95309.836% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -6429.023% |
| International Stem Cell Corporation | 2.59 Million USD | -11135.521% |
| Bioxytran, Inc. | 1.89 Million USD | -15224.549% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -466149.019% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -13243.115% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -8374.083% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -3302.315% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -37564.686% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 23380.0% |
| Neutra Corp. | 52.18 Thousand USD | -557510.133% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 11791.442% |
| PureTech Health plc | -167.19 Million USD | 274.046% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 118920.128% |
| IXICO plc | -4.44 Million USD | 6647.29% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -2101.377% |
| Gelesis Holdings, Inc. | 54.85 Million USD | -430.528% |
| CSL Limited | 10.52 Billion USD | 97.235% |
| Cellectis S.A. | -43.81 Million USD | 764.097% |